85817-34-1

Basic information

• Product Name: 4-N-BENZYL-2-HYDROXYMETHYLPIPERAZINE
• Synonyms: 4-Benzyl-2-(hydroxymethyl)piperazine;1-Benzyl-3-(hydroxymethyl)piperazine;(4-Benzylpiperazin-2-yl)methanol;B67335;2-Piperazinemethanol, 4-(phenylmethyl)-;4-(phenylMethyl)-2-piperazineMethanol;1-Benzyl-3-(hydroxymethyl)piperazine 2HCl;4-(Benzyl)-2-piperazinemethanol
• CAS NO: 85817-34-1
• Molecular Formula: C₁₂H₁₈N₂O
• Molecular Weight: 206.28
• Product Categories: pharmacetical
• Mol File: 85817-34-1.mol

Chemical Properties

• Boiling Point: 318.1°C at 760 mmHg
• Flash Point: 146.2°C
• Appearance: /
• Density: 1.083g/cm³
• Vapor Pressure: 0.000154mmHg at 25°C
• Refractive Index: 1.551
• Storage Temp.: 2-8°C(protect from light)
• PKA: 14.97±0.10(Predicted)
• CAS DataBase Reference: 4-N-BENZYL-2-HYDROXYMETHYLPIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-N-BENZYL-2-HYDROXYMETHYLPIPERAZINE(85817-34-1)
• EPA Substance Registry System: 4-N-BENZYL-2-HYDROXYMETHYLPIPERAZINE(85817-34-1)

Safety Data

• Hazardous Substances Data: 85817-34-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-N-Benzyl-2-hydroxymethylpiperazine is used as a building block for the synthesis of various bioactive molecules, contributing to the development of new drugs with potential therapeutic applications.
Used in Antiviral Applications:
4-N-Benzyl-2-hydroxymethylpiperazine is used as a potential antiviral agent, with its properties being studied for effectiveness against various viral infections.
Used in Anticancer Applications:
4-N-Benzyl-2-hydroxymethylpiperazine is used as a potential anticancer agent, with research focusing on its ability to target and inhibit the growth of cancer cells.
Used in Coordination Chemistry:
4-N-Benzyl-2-hydroxymethylpiperazine is used as a ligand in coordination chemistry, playing a role in the formation of metal complexes with potential applications in various fields.
Used in Neurological Disorder Treatment:
4-N-Benzyl-2-hydroxymethylpiperazine is used as a potential agent for the treatment of neurological disorders, with its properties being evaluated for efficacy in managing symptoms and improving patient outcomes.

InChI:InChI=1/C12H18N2O/c15-10-12-9-14(7-6-13-12)8-11-4-2-1-3-5-11/h1-5,12-13,15H,6-10H2

Upstream product

• 936553-15-0 tert-butyl 4-benzyl-2-(hydroxymethyl)piperazine-1-carboxylate 
• 181955-94-2 4-benzylpiperazine-2-carboxylic acid methyl ester 
• 584-08-7 potassium carbonate 
• 7757-82-6 sodium sulfate 
• 140-28-3 N,N'-Dibenzylethylenediamine 
• 149648-70-4 ethyl 3-oxo-1,4-bis(phenylmethyl)-2-piperazinecarboxylate 
• 149648-71-5 ethyl 3-oxo-4-(phenylmethyl)-2-piperazinecarboxylate 

Downstream Products

• 126766-44-7 1-<(3,4-dichlorophenyl)acetyl>-4-(phenylmethyl)-2-piperazinemethanol 
• 122323-87-9 2-piperazinemethanol dihydrochloride 
• 936553-19-4 2-[4-benzyl-2-(hydroxymethyl)piperazin-1-yl]-6-nitroquinoline 
• 936553-15-0 tert-butyl 4-benzyl-2-(hydroxymethyl)piperazine-1-carboxylate 
• 1252646-89-1 methyl 2-(4-benzyl-2-(hydroxymethyl)piperazin-1-yl)-5-nitrobenzoate 
• 937047-40-0 1-(4-benzyl-2-hydroxymethyl-piperazin-1-yl)-2-chloro-ethanone 
• 936553-16-1 7-benzylhexahydrooxazolo[3,4-a]pyrazin-3-one 
• 110-85-0 piperazine 
• 133407-24-6 4-[2-(3,4-Dichloro-phenyl)-acetyl]-3-(3-oxo-pyrrolidin-1-ylmethyl)-piperazine-1-carboxylic acid methyl ester 

Relevant articles and documents

Discovery of novel leukotriene A4 hydrolase inhibitors based on piperidine and piperazine scaffolds

Novel piperidine and piperazine derivatives have been designed and tested as inhibitors of LTA4 hydrolase (LTA4H). Most potent compounds showed good potency in both enzymatic and functional human whole blood assay. Crystallography studies further confirmed observed structure-activity relationship and LTA4H binding mode for analogs from the piperidine series.

MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF

The present application relates to 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine, 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,5]benzodiazepine, 2,3,4,4a,5,6,7,11b-octahydro-1H-pyrido[3,4-d][2]benzazepine, 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1]benzazepine, 1,2,3,4,4a,5-hexahydro-7H-pyrazino[1,2-a][4,1]benzoxazepine, and 2,3,4,4a,5,6-hexahydro-1H-pyrazino[2,1-d][1,5]benzoxazepine, and 5,6,7,7a,8,9,10,11-octahydropyrazino[1,2-d]pyrido[3,2-b][1,4]diazepine derivatives of formula (I) wherein R1, R2, R3, R4, R5, R6, X1, X2, X3, X4, Y1, Y2, and Y3 are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

Substituted 1,4-piperazine-heteroaryl derivatives as 5-HT1D receptor agonists

A class of 1,4-disubstituted piperazine derivatives, further substituted on one of the carbon atoms of the piperazine ring, are selective agonists of 5-HT1 -like receptors, being potent agonists of the human 5-HT1Dα receptor subtype whilst possessing at least a 10-fold selective affinity for the 5-HT1Dα receptor subtype relative to the 5-HT1Dβ subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT1D receptors is indicated, while eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT1D receptor agonists.

A potent new class of κ-receptor agonist: 4-Substituted 1-(arylacetyl)- 2-[(dialkylamino)methyl]piperazines

The synthesis of 4-substituted 1-(arylacetyl)-2- [(alkylamino)methyl]piperazines (10-22, 26, 27, and 30-33) and their activities as κ-opioid receptor agonists are described. This includes a range of 4-acyl and 4-carboalkoxy derivatives with the latter ser